REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 Results
Thomas Norton(Anna Needs Neuroblastoma Answers), Ximena Graber(Anna Needs Neuroblastoma Answers), Shazia Ali(Regeneron (United States)), Andrea T. Hooper(Regeneron (United States)), Cynthia X. Pan(Anna Needs Neuroblastoma Answers), Ned Braunstein(Anna Needs Neuroblastoma Answers), Rafia Bhore(Bristol-Myers Squibb (Germany)), Yuhwen Soo(Regeneron (United States)), Romana Hosain(Anna Needs Neuroblastoma Answers), Anita Kohli(Anna Needs Neuroblastoma Answers), Jennifer D. Hamilton(Regeneron (United States)), Leah Lipsich(Anna Needs Neuroblastoma Answers), Sumathi Sivapalasingam(Anna Needs Neuroblastoma Answers), Christina J. Perry(Florey Institute of Neuroscience and Mental Health), Bret J. Musser(Regeneron (United States)), Alina Baum(Regeneron (United States)), Haitao Gao(Novartis (United States)), Bari Kowal(Anna Needs Neuroblastoma Answers), Gregory P. Geba(Regeneron (United States)), Joseph Im(Anna Needs Neuroblastoma Answers), Joseph A. Bocchini(Louisiana State University Health Sciences Center New Orleans), Christos A. Kyratsous(Regeneron (United States)), Diana Rofail(Regeneron (United States)), Neil Stahl(Arthritis and Rheumatism Associates), Gerard Acloque(Unknown), Gary Herman(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Yessica Sachdeva(Anna Needs Neuroblastoma Answers), A. Thomas DiCioccio(Regeneron (United States)), Wendy Kampman(Anna Needs Neuroblastoma Answers), Yun‐Ji Kim(Anna Needs Neuroblastoma Answers), David M. Weinreich(Regeneron (United States)), K. C. Turner(Regeneron (United States)), Adnan Mahmood(Anna Needs Neuroblastoma Answers), John D. Davis(Providence College), Amanda Cook(Harvard University)
Cited by 19
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k